Researchers from Johns Hopkins have identified a marker, Mig6, that in early studies has been able to predict longer survival among patients taking the EGFR tyrosine kinase inhibitors gefitinib (Astra Zeneca's Iressa) and erlotinib (Genenetech's Tarceva).
Originally published May 14.
Smoking, most people have come to accept, is a major cause of lung cancer. But each year in the US, up to 24,000 men and women who have never smoked still end up dying from the disease.
In the first quarter of this year, pharmacogenetically targeted cancer drugs Xalkori and Zelboraf had marked increases in revenues from the previous year's quarter.
Boehringer Ingelheim has launched a campaign to educate healthcare providers about biomarker testing to personalize treatment for non-small cell lung cancer patients.
